Ordin nr. 1301/500/2008 din 11 iulie 2008 Partea a ii-a

Nu se va prescrie în regim compensat pentru tratamentul litiazei biliare.
Se aplică tuturor denumirilor comerciale, formelor farmaceutice şi concentraţiilor corespunzătoare DCI-ului.
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

A05AA02 ACIDUM CAPS. 250 mg

URSODEOXYCHOLICUM

URSOFALK(R) 250 mg DR. FALK PHARMA GMBH

URSOSAN 250 mg PRO. MED. CS PRAHA AS

________________________________________________________________________________

______________________________________________________________________________

| 875 |B01AB08| REVIPARINUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

B01AB08 REVIPARINUM SOL. INJ. 1432 ui/0.25 ml

CLIVARIN(R) 1432 UI/0.25 ml 1432 ui/0.25 ml ABBOTT GMBH & CO. KG
B01AB08 REVIPARINUM SOL. INJ. 3436 ui/0.6 ml

CLIVARIN(R) 3436 UI/0.6 ml 3436 ui/0.6 ml ABBOTT GMBH & CO. KG

________________________________________________________________________________
#M4

______________________________________________________________________________

| 878 | *** Abrogată |

|_______|______________________________________________________________________|
______________________________________________________________________________

| 879 | *** Abrogată |

|_______|______________________________________________________________________|
#B

______________________________________________________________________________

| 880 |J01CR03| TICARCILLINUM + ACIDUM CLAVULANICUM | |

|_______|_______|____________________________________________|_________________|

________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

J01CR03 TICARCILLINUM + PULB. PT. SOL. 3.2 g

ACIDUM CLAVULANICUM INJ./PERF.

TIMENTIN 3,2 g 3.2 g BEECHAM GROUP PLC

________________________________________________________________________________
______________________________________________________________________________

| 881 |J01CR05| PIPERACILLINUM + TAZOBACTAMUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

J01CR05 PIPERACILLINUM + LIOF. PT. SOL. INJ.

TAZOBACTAMUM

TAZOCIN 2,25 WYETH LEDERLE PHARMA GMBH

TAZOCIN 4,5 WYETH LEDERLE PHARMA GMBH

________________________________________________________________________________

______________________________________________________________________________

| 882 |J01DH02| MEROPENEMUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

J01DH02 MEROPENEMUM PULB. PT. SOL. INJ. 1 g

I.V./PERF.

MERONEM IV 1 g 1 g ASTRAZENECA UK LTD.

J01DH02 MEROPENEMUM PULB. PT. SOL. INJ. 500 mg

I.V./PERF.

MERONEM IV 500 mg 500 mg ASTRAZENECA UK LTD.

________________________________________________________________________________

______________________________________________________________________________

| 883 |J01DH51| IMIPENEMUM + CILASTATINUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

J01DH51 IMIPENEMUM + PULB. PT. SOL. PERF.

CILASTATINUM

TIENAM I.V. MERCK SHARP & DOHME

ROMANIA S.R.L.

________________________________________________________________________________

______________________________________________________________________________

| 884 |J01XA01| VANCOMYCINUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

J01XA01 VANCOMYCINUM LIOF. PT. SOL. PERF. 1 g

VANCOMYCIN TEVA 1 g TEVA PHARM. WORKS PRIVATE

LTD. COMPANY

J01XA01 VANCOMYCINUM PULB. LIOF. PT. SOL. 1 g

PERF./INJ

EDICIN 1 g LEK PHARMACEUTICALS D.D.
J01XA01 VANCOMYCINUM LIOF. PT. SOL. PERF. 500 mg

VANCOMYCIN TEVA 500 mg TEVA PHARM. WORKS PRIVATE

LTD. COMPANY
J01XA01 VANCOMYCINUM LIOF. PT. SOL. 500 mg

PERF./INJ.

EDICIN 500 mg LEK PHARMACEUTICALS D.D.

________________________________________________________________________________

______________________________________________________________________________

| 885 |J01XA02| TEICOPLANINUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

J01XA02 TEICOPLANINUM LIOF. + SOLV. PT. SOL. 400 mg

INJ.

TARGOCID(R) 400 mg 400 mg AVENTIS PHARMA LTD.

________________________________________________________________________________
______________________________________________________________________________

| 887 |J01XX08| LINEZOLIDUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

J01XX08 LINEZOLIDUM GRAN. PT. SUSP. ORALA 100 mg/5 ml

ZYVOXID(R) 100 mg/5 ml PFIZER EUROPE MA EEIG
J01XX08 LINEZOLIDUM SOL. PERF. 2 mg/ml

ZYVOXID(R) 2 mg/ml PFIZER EUROPE MA EEIG

J01XX08 LINEZOLIDUM COMPR. FILM. 600 mg

ZYVOXID(R) 600 mg PFIZER EUROPE MA EEIG

________________________________________________________________________________
______________________________________________________________________________

| 888 |J02AC01| FLUCONAZOLUM | |

|_______|_______|____________________________________________|_________________|
Prescriere limitată: Tratament de întreţinere la pacienţi cu meningită